MedPath

Billroth II or Roux-en-Y Reconstruction for GJ After PD: Randomized Controlled Trial (PAUDA TRIAL)

Not Applicable
Completed
Conditions
Malignant Neoplasm of Head of Pancreas
Interventions
Procedure: Pancreaticoduodenectomy
Registration Number
NCT02246205
Lead Sponsor
Hospital Universitari de Bellvitge
Brief Summary

The aim of the study is to compare the effect of Roux-en Y reconstruction (study group, DPCDA) versus classical Child reconstruction (DPCUN) in the incidence of VGL in patients for DPC. The hypotesis of the study is that Roux-en Y reconstruction decreases incidence of DGE after pancreaticoduodenectomy.

Detailed Description

The pancreaticoduodenectomy (DPC) is the procedure of choice of the tumors of the head of the pancreas, periampullary tumors and intractable inflammatory pathology.

The high postoperative morbidity (50%) involve a mean hospital stay of 15 days after surgery. The most common complication is delayed gastric emptying (DGE), defined as the intolerance to solid oral intake by 7th day postoperative. In some severe cases, oral intolerance can occur after the 21th postoperative day. Therefore, the patient requires parenteral nutrition and prolonged hospital stay.

The aim of the study is to compare the effect of Roux-en Y reconstruction (study group, DPCDA) versus classical Child reconstruction (DPCUN) in the incidence of VGL in patients for DPC.

The hypotesis of the study is that Roux-en Y reconstruction decreases incidence of DGE after pancreaticoduodenectomy.

A pilot randomized clinical trial has been designed to compare two surgical techniques for reconstruction of digestive tract after DPC in patients treated in our center. The patients are randomized after tumor resection and before the reconstruction througt computer-generated random numbers using a sealed envelope technique. The primary endpoint is the incidence of DGE. Secondary endpoints are postoperative morbidity and specific complications as pancreatic fistula, the hospital stay, and postoperative endocrine and exocrine function.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Patients with pancreatic head cancer considered resectable after the extension study
  • Patients suffering from periampullary tumors considered resectable after the extension study
  • Patients suffering from pancreatic inflammatory disease with medically intractable pain
  • Patients who have read the information sheet of the study and signed the informed consent form
Exclusion Criteria
  • Patients with history of previous gastrectomy
  • Patients with associated resections of other organs, except for the superior portal vein or mesenteric vein
  • Patients with enlargement to total pancreatectomy
  • Patients who has recieved neoadjuvant treatment
  • Patients with plastic peritonitis
  • Patients with liver cirrhosis.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DPC DNPancreaticoduodenectomyRoux-en Y reconstruction after pancreaticoduodenectomy
DPC UNPancreaticoduodenectomyChild reconstruction after pancreaticoduodenectomy
Primary Outcome Measures
NameTimeMethod
Delayed gastric emptying incidence after pancreaticoduodenectomywithin the first 60 daysafter surgery

DGE, defined as oral diet intolerance from the 7th postoperative day, and the persistence of nasogastric tube on the 4th postoperative day or later, according to the ISGPS criteria

Secondary Outcome Measures
NameTimeMethod
Morbidity and complications after pancreaticoduodenectomywithin the first 60 daysafter surgery

Postoperative morbidity was defined as any complication that appeared during hospital admission. Postoperative complications and postoperative mortality were defined according to the Clavien-Dindo classification.

Trial Locations

Locations (1)

Hospital Universitari de Bellvitge

🇪🇸

Hospitalet Llobregat, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath